Iodine I 131/Tositumomab

drug-information.ru

|Iodine I 131/Tositumomab

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Iodine I 131/Tositumomab


Generic Name: Iodine I 131/Tositumomab (EYE-oh-dine/tos-IT-too-moe-mab)
Brand Name: Bexxar 131 Iodine

Iodine I 131/Tositumomab may cause serious allergic reactions, especially in patients who have received murine proteins previously. Seek immediate medical attention if you experience rash, itching, swelling, severe dizziness, or trouble breathing. Iodine I 131/Tositumomab may cause serious (possibly life-threatening) decreases in the number of white blood cells and platelets your body produces. This effect may last for a long period of time. Additional treatment may be needed to manage this effect. Serious infections or bleeding could occur as a result of low blood cell levels. Contact your doctor immediately if you experience fever, persistent sore throat, any other sign of infection, or unusual bruising or bleeding. Iodine I 131/Tositumomab must not be used during pregnancy because fetal harm can result. Contact your doctor immediately if you suspect that you could be pregnant.


Iodine I 131/Tositumomab is used for:

Treating certain forms of non-Hodgkin lymphoma in patients who have not responded to other therapy.

Iodine I 131/Tositumomab is a radioactive monoclonal antibody protein. It works by recognizing a protein receptor on cancer cells and then delivering radiation that increases the killing effect of the antibody.

Do NOT use Iodine I 131/Tositumomab if:

  • you are allergic to any ingredient in Iodine I 131/Tositumomab or to mouse proteins
  • you have bone marrow depression or a serious blood disorder such as low hemoglobin, white blood cells, or platelets
  • you are pregnant
  • you are unable to take a thyroid blocker (eg, methimazole)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Iodine I 131/Tositumomab :

Some medical conditions may interact with Iodine I 131/Tositumomab . Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

  • if you are planning to become pregnant or are breast-feeding
  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you have an infection, thyroid problems, or kidney problems
  • if you are scheduled to receive a vaccine

Some MEDICINES MAY INTERACT with Iodine I 131/Tositumomab . Tell your health care provider if you are taking any other medicines, especially any of the following:

  • Medicines that decrease blood clotting (eg, aspirin, clopidogrel, ibuprofen, warfarin) and medicines that affect the immune system (eg, azathioprine, corticosteroids, cyclosporine) because serious side effects, such as risk of bleeding or infections, may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Iodine I 131/Tositumomab may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Iodine I 131/Tositumomab :

Use Iodine I 131/Tositumomab as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Iodine I 131/Tositumomab is usually administered as an injection at your doctor"s office, hospital, or clinic. Ask your doctor any question that you may have about Iodine I 131/Tositumomab .
  • If you miss a dose of Iodine I 131/Tositumomab , contact your doctor right away.

Ask your health care provider any questions you may have about how to use Iodine I 131/Tositumomab .

Important safety information:

  • Iodine I 131/Tositumomab may cause dizziness or drowsiness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Iodine I 131/Tositumomab . Using Iodine I 131/Tositumomab alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.
  • Iodine I 131/Tositumomab may reduce the number of certain blood cells, including red blood cells, white blood cells, and platelets. This may increase your risk of infection and bleeding. Prevent infection by avoiding contact with people with colds or other infections. Do not touch your eyes or the inside of your nose unless you have thoroughly washed your hands first. Notify your doctor of any signs of infection, including fever, sore throat, rashes, or chills. To prevent bleeding, avoid situations in which bruising or injury may occur. Report any unusual bleeding or bruising; blood in stools; or black, tarry stools to your doctor.
  • Avoid vaccinations with live virus vaccines (eg, measles, mumps, oral polio) while you are taking Iodine I 131/Tositumomab .
  • As with other cancer medicines, Iodine I 131/Tositumomab can cause a secondary cancer. Discuss the benefits and risks of using Iodine I 131/Tositumomab with your doctor.
  • After receiving Iodine I 131/Tositumomab , the radioactive part of the dose will be in your body for several days. Follow all instructions you are given to minimize the exposure of others around you to this radioactivity.
  • Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Iodine I 131/Tositumomab .
  • Iodine I 131/Tositumomab may reduce the levels of thyroid hormone your thyroid produces. Thyroid tests will be done before your doses and every year thereafter to monitor for any change in function of the thyroid gland.
  • Some patients may develop an immune response called HAMA (human anti-murine antibody) after using Iodine I 131/Tositumomab . This antibody may interfere with certain lab test results. Be sure all of your doctors and laboratory personnel know that you are being treated, or have been treated, with Iodine I 131/Tositumomab .
  • Both men and women capable of having children who receive Iodine I 131/Tositumomab should use reliable methods of birth control (eg, condoms) during and for at least 1 year after receiving Iodine I 131/Tositumomab .
  • LAB TESTS, including complete blood cell counts, platelet counts, thyroid function tests, and kidney function tests, will be required to monitor your progress and check for side effects. Frequent monitoring will be done for up to 12 weeks after treatment. Be sure to keep all doctor and lab appointments.
  • Caution is advised when using Iodine I 131/Tositumomab in the ELDERLY because they may be more sensitive to the effect Iodine I 131/Tositumomab has on blood cells.
  • PREGNANCY and BREAST-FEEDING: Do not use Iodine I 131/Tositumomab if you are pregnant. If you think that you may be pregnant, contact your doctor immediately. Iodine I 131/Tositumomab is excreted in breast milk. Do not breast-feed while receiving Iodine I 131/Tositumomab .

Possible side effects of Iodine I 131/Tositumomab :

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; headache; muscle aches; nausea; pain, swelling, or redness at the injection site; stomach upset; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black stools; easy bruising or bleeding; fast heartbeat; flu-like symptoms such as chills, cough, or sweating; infection; itching; lightheadedness; loss of appetite; lung infection; new growths or lumps; pain, including chest, stomach, muscle, neck, back, or joint pain; pale skin; persistent sore throat or fever; shortness of breath; sudden weight loss; swelling of the hands or feet; unusual tiredness or weakness; vomit that looks like coffee grounds.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org/findyour.htm), or emergency room immediately.

Proper storage of Iodine I 131/Tositumomab :

Iodine I 131/Tositumomab is radioactive and must be stored in the lead pot provided. It is usually handled and stored by a health care professional. Keep Iodine I 131/Tositumomab out of reach of children and away from pets.

General information:

  • If you have any questions about Iodine I 131/Tositumomab , please talk with your doctor, pharmacist, or other health care provider.
  • Iodine I 131/Tositumomab is to be used only by the patient for whom it is prescribed. Do not share it with other people.
  • If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Iodine I 131/Tositumomab . If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: November 1, 2006
Database Edition 06.4.1.002
Copyright © 2006 Wolters Kluwer Health, Inc.




Where can I get more information about Iodine I 131/Tositumomab ? We recommend to use www.Drugs.com

Typical mistypes for Iodine I 131/Tositumomab
uodine i 131/tositumomab, jodine i 131/tositumomab, kodine i 131/tositumomab, oodine i 131/tositumomab, 9odine i 131/tositumomab, 8odine i 131/tositumomab, iidine i 131/tositumomab, ikdine i 131/tositumomab, ildine i 131/tositumomab, ipdine i 131/tositumomab, i0dine i 131/tositumomab, i9dine i 131/tositumomab, iosine i 131/tositumomab, ioxine i 131/tositumomab, iocine i 131/tositumomab, iofine i 131/tositumomab, iorine i 131/tositumomab, ioeine i 131/tositumomab, iodune i 131/tositumomab, iodjne i 131/tositumomab, iodkne i 131/tositumomab, iodone i 131/tositumomab, iod9ne i 131/tositumomab, iod8ne i 131/tositumomab, iodibe i 131/tositumomab, iodime i 131/tositumomab, iodije i 131/tositumomab, iodihe i 131/tositumomab, iodinw i 131/tositumomab, iodins i 131/tositumomab, iodind i 131/tositumomab, iodinr i 131/tositumomab, iodin4 i 131/tositumomab, iodin3 i 131/tositumomab, iodine u 131/tositumomab, iodine j 131/tositumomab, iodine k 131/tositumomab, iodine o 131/tositumomab, iodine 9 131/tositumomab, iodine 8 131/tositumomab, iodine i 231/tositumomab, iodine i q31/tositumomab, iodine i 121/tositumomab, iodine i 1w1/tositumomab, iodine i 1e1/tositumomab, iodine i 141/tositumomab, iodine i 132/tositumomab, iodine i 13q/tositumomab, iodine i 131/rositumomab, iodine i 131/fositumomab, iodine i 131/gositumomab, iodine i 131/yositumomab, iodine i 131/6ositumomab, iodine i 131/5ositumomab, iodine i 131/tisitumomab, iodine i 131/tksitumomab, iodine i 131/tlsitumomab, iodine i 131/tpsitumomab, iodine i 131/t0situmomab, iodine i 131/t9situmomab, iodine i 131/toaitumomab, iodine i 131/tozitumomab, iodine i 131/toxitumomab, iodine i 131/toditumomab, iodine i 131/toeitumomab, iodine i 131/towitumomab, iodine i 131/tosutumomab, iodine i 131/tosjtumomab, iodine i 131/tosktumomab, iodine i 131/tosotumomab, iodine i 131/tos9tumomab, iodine i 131/tos8tumomab, iodine i 131/tosirumomab, iodine i 131/tosifumomab, iodine i 131/tosigumomab, iodine i 131/tosiyumomab, iodine i 131/tosi6umomab, iodine i 131/tosi5umomab, iodine i 131/tositymomab, iodine i 131/tosithmomab, iodine i 131/tositjmomab, iodine i 131/tositimomab, iodine i 131/tosit8momab, iodine i 131/tosit7momab, iodine i 131/tositunomab, iodine i 131/tositukomab, iodine i 131/tositujomab, iodine i 131/tositumimab, iodine i 131/tositumkmab, iodine i 131/tositumlmab, iodine i 131/tositumpmab, iodine i 131/tositum0mab, iodine i 131/tositum9mab, iodine i 131/tositumonab, iodine i 131/tositumokab, iodine i 131/tositumojab, iodine i 131/tositumomzb, iodine i 131/tositumomsb, iodine i 131/tositumomwb, iodine i 131/tositumomqb, iodine i 131/tositumomav, iodine i 131/tositumoman, iodine i 131/tositumomah, iodine i 131/tositumomag, odine i 131/tositumomab, idine i 131/tositumomab, ioine i 131/tositumomab, iodne i 131/tositumomab, iodie i 131/tositumomab, iodin i 131/tositumomab, iodinei 131/tositumomab, iodine 131/tositumomab, iodine i131/tositumomab, iodine i 31/tositumomab, iodine i 11/tositumomab, iodine i 13/tositumomab, iodine i 131tositumomab, iodine i 131/ositumomab, iodine i 131/tsitumomab, iodine i 131/toitumomab, iodine i 131/tostumomab, iodine i 131/tosiumomab, iodine i 131/tositmomab, iodine i 131/tosituomab, iodine i 131/tositummab, iodine i 131/tositumoab, iodine i 131/tositumomb, iodine i 131/tositumoma, oidine i 131/tositumomab, idoine i 131/tositumomab, ioidne i 131/tositumomab, iodnie i 131/tositumomab, iodien i 131/tositumomab, iodin ei 131/tositumomab, iodinei 131/tositumomab, iodine i131/tositumomab, iodine i1 31/tositumomab, iodine i 311/tositumomab, iodine i 113/tositumomab, iodine i 13/1tositumomab, iodine i 131t/ositumomab, iodine i 131/otsitumomab, iodine i 131/tsoitumomab, iodine i 131/toistumomab, iodine i 131/tostiumomab, iodine i 131/tosiutmomab, iodine i 131/tositmuomab, iodine i 131/tosituommab, iodine i 131/tositummoab, iodine i 131/tositumoamb, iodine i 131/tositumomba, iiodine i 131/tositumomab, ioodine i 131/tositumomab, ioddine i 131/tositumomab, iodiine i 131/tositumomab, iodinne i 131/tositumomab, iodinee i 131/tositumomab, iodine i 131/tositumomab, iodine ii 131/tositumomab, iodine i 131/tositumomab, iodine i 1131/tositumomab, iodine i 1331/tositumomab, iodine i 1311/tositumomab, iodine i 131//tositumomab, iodine i 131/ttositumomab, iodine i 131/toositumomab, iodine i 131/tossitumomab, iodine i 131/tosiitumomab, iodine i 131/tosittumomab, iodine i 131/tosituumomab, iodine i 131/tositummomab, iodine i 131/tositumoomab, iodine i 131/tositumommab, iodine i 131/tositumomaab, iodine i 131/tositumomabb, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved